Abstract:
INTRODUCTION:Claims data (IBM MarketScan Commercial and MarketScan Medicare Supplemental databases) from June 30, 2011 to September 30, 2017 were used to evaluate the cost impact of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in this retrospective cohort study. METHODS:The primary analysis compared short-term costs for patients diagnosed with HER2+ MBC at least 180 days after the end of first HER2-targeted treatment (MBC+ cohort) versus a propensity score matched cohort of patients with breast cancer who did not develop MBC (MBC- cohort). A pseudo-post period for patients in the HER2+ MBC- cohort was defined by indexing to the HER2+ treatment completion-MBC diagnosis time interval of the matched pair in the HER2+ MBC+ cohort; we then compared average monthly cost differences between these groups for the year preceding and following MBC diagnosis. In secondary analyses, we estimated medium-term aggregate and categorical healthcare costs for patients with HER2+ MBC up to 3 years post-diagnosis. RESULTS:In the short-term primary analysis, costs for the HER2+ MBC+ and HER2+ MBC- cohorts were largely comparable in the year preceding MBC diagnosis. Monthly direct costs were significantly higher for the HER2+ MBC+ cohort in the months immediately preceding MBC diagnosis, with differences in the range of $500-5000. Following diagnosis, total monthly costs were $13,000-34,000 higher for patients in the HER2+ MBC+ cohort vs. the HER2+ MBC- cohort. In the medium-term secondary analysis, mean per patient total costs were $218,171 [standard error (SE) $5450] in the first year following MBC diagnosis and $412,903 (SE $13,034) cumulatively over 3 years following diagnosis (among patients with complete follow-up). Primary cost contributors were outpatient visits ($195,162; SE $8043) and HER2-targeted therapy drug costs ($177,489; SE $8120). CONCLUSIONS:HER2+ MBC is associated with high short-term and medium-term direct healthcare costs. These could be alleviated with early diagnosis and optimal standard-of-care treatment for early breast cancer, which can significantly reduce the risk of recurrence.
journal_name
Adv Therjournal_title
Advances in therapyauthors
Sussell JA,Sheinson D,Wu N,Shah-Manek B,Seetasith Adoi
10.1007/s12325-020-01283-4subject
Has Abstractpub_date
2020-04-01 00:00:00pages
1632-1645issue
4eissn
0741-238Xissn
1865-8652pii
10.1007/s12325-020-01283-4journal_volume
37pub_type
杂志文章abstract:BACKGROUND:Previous studies showed the relation of mental distress such as anxiety and depression to coronary vasoconstriction and myocardial ischemia. However, the mental health status of patients suspected to have vasospastic angina is unclear. METHODS:A total of 99 patients underwent intracoronary acetylcholine (AC...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01424-9
更新日期:2020-09-01 00:00:00
abstract:INTRODUCTION:Aripiprazole and olanzapine are atypical antipsychotics. Both drugs can induce metabolic changes; however, the metabolic side effects produced by aripiprazole are more benign. The aim of the study was to evaluate if aripiprazole and olanzapine alter prolactin levels, lipid and glucose metabolism and hepati...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01566-w
更新日期:2020-12-05 00:00:00
abstract::Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin-converting enzyme 2 (ACE2) widely expressing in arterial and venous endothelial cells and arterial smooth muscle cells has been identified as a functional rec...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01399-7
更新日期:2020-07-01 00:00:00
abstract::Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-cell lung cancer. Lorlatinib is a novel third-generation ALK TKI that i...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01365-3
更新日期:2020-06-01 00:00:00
abstract::Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the "gold standard" for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that tr...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-018-0805-y
更新日期:2018-11-01 00:00:00
abstract::Brucellosis remains an important public health problem in Turkey, just as it is in other regions of the world. This study was conducted to determine the types and rates of cutaneous lesions that occur in patients with brucellosis. Brucellosis was diagnosed by standard tube agglutination testing for Brucella antibodies...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02849964
更新日期:2007-07-01 00:00:00
abstract::X-linked hypophosphataemia (XLH) is the most prevalent form of hereditary rickets characterized by an alteration of phosphate metabolism which frequently leads to the appearance of fractures, bone deformities and growth delay. Although the mechanism of growth impairment in patients with XLH still needs to be clarified...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-019-01178-z
更新日期:2020-05-01 00:00:00
abstract:INTRODUCTION:Transient hepatic attenuation differences (THAD) are areas of high parenchymal enhancement observed during the hepatic arterial phase on computed tomography (CT). THAD in the left lobe of the liver can lead to surgical complications. METHODS:A retrospective study was conducted on patients who underwent mu...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01428-5
更新日期:2020-09-01 00:00:00
abstract::In the original article. The third author name is incorrect. The correct name is Nicholas J. Leeper. ...
journal_title:Advances in therapy
pub_type: 已发布勘误
doi:10.1007/s12325-020-01220-5
更新日期:2020-02-01 00:00:00
abstract:INTRODUCTION:Benefit and risk of anticoagulation in cirrhotic patients with portal vein thrombosis (PVT) remain controversial, especially in those with asymptomatic PVT and in non-liver transplant candidates. Furthermore, the predictors of portal vein recanalization and bleeding events after anticoagulation are critica...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01550-4
更新日期:2020-11-05 00:00:00
abstract::Eupatorium laevigatum Lam. is a plant common to the central region of Brazil, where it is a widely used remedy for lesions such as buccal aphthae. These painful inflammatory ulcers affect 50% of the general population. For the first part of this two-part study, a phytotherapeutic preparation from E. laevigatum extract...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1007/BF02850010
更新日期:2000-11-01 00:00:00
abstract:INTRODUCTION:The aim of the study was to investigate the role of the proteolytic fraction from Vasconcellea cundinamarcensis, designated as P1G10, on the healing of chronic foot ulcers in neuropathic patients with diabetes 2. METHODS:Fifty patients were enrolled in a prospective, randomized, double-blind trial, to ver...
journal_title:Advances in therapy
pub_type: 杂志文章,随机对照试验
doi:10.1007/s12325-018-0684-2
更新日期:2018-04-01 00:00:00
abstract::Alpha-mannosidosis is a rare lysosomal storage disorder that generally presents in early childhood. It is a progressive, highly heterogeneous disease that is difficult to recognize, and a diagnosis is usually reached after referrals to multiple specialists. It is important to understand the challenges faced by patient...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01574-w
更新日期:2020-11-24 00:00:00
abstract::The aim of this prospective, randomized, open-label, blinded endpoint (PROBE) study was to compare the antihypertensive efficacy of 2 angiotensin II (AII) receptor antagonists with different pharmacologic profiles, valsartan and olmesartan, in patients with mild-to-moderate essential hypertension. After an initial 2-w...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1007/BF02850182
更新日期:2005-01-01 00:00:00
abstract:INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is limited. METHODS:We u...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01380-4
更新日期:2020-07-01 00:00:00
abstract:INTRODUCTION:Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. It is vitally important to predict prognosis and restrict unnecessary adjuvant treatments for patients with ACC. This study aims to confirm the prognostic value of Ki-67 and provide a prognostic evaluation on ACC after primary surgery...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01050-0
更新日期:2019-10-01 00:00:00
abstract:INTRODUCTION:Well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are often slow-growing, and some patients with unresectable, asymptomatic, non-functioning tumors may face the choice between watchful waiting (WW), or somatostatin analogues (SSA) to delay progression. We developed ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-017-0653-1
更新日期:2018-01-01 00:00:00
abstract:INTRODUCTION:High-dose intravenous esomeprazole is the only approved pharmacological treatment for the prevention of peptic ulcer rebleeding (currently approved in over 100 countries worldwide), but has not yet been approved in China. This study aimed to evaluate a high-dose esomeprazole intravenous regimen vs. an acti...
journal_title:Advances in therapy
pub_type: 杂志文章,随机对照试验
doi:10.1007/s12325-015-0265-6
更新日期:2015-11-01 00:00:00
abstract:INTRODUCTION:The European Medicines Agency (EMA) requires vaccine manufacturers to conduct enhanced safety surveillance (ESS) of seasonal influenza vaccines including a near real-time evaluation of collected data. The objective was to identify whether the use of passive surveillance or active surveillance provides diff...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-018-0747-4
更新日期:2018-08-01 00:00:00
abstract::This multicenter, double-masked, randomized, parallel-group study compared the efficacy and safety of ketorolac tromethamine 0.5% ophthalmic solution with levocabastine 0.05% and ketorolac tromethamine vehicle in patients with seasonal allergic conjunctivitis. One drop of ketorolac, levocabastine, or vehicle was insti...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1007/BF02854842
更新日期:2000-03-01 00:00:00
abstract::Cardiovascular diseases (CVDs) are the leading cause of premature deaths globally and in Ukraine. Dyslipidemia is a recognized risk factor for the development of CVD. Therefore, early detection and appropriate management of dyslipidemia are essential for the primary prevention of CVDs. However, currently, there is a l...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-020-01490-z
更新日期:2020-11-01 00:00:00
abstract:INTRODUCTION:Rivastigmine is a cholinesterase inhibitor, approved for the treatment of mild-to-moderate dementia of Alzheimer's type. This study assessed the short- and long-term effectiveness and safety of rivastigmine in patients with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting in Taiwa...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/s12325-019-00939-0
更新日期:2019-06-01 00:00:00
abstract::In the original article, under the "Access to treatment" heading. ...
journal_title:Advances in therapy
pub_type: 已发布勘误
doi:10.1007/s12325-020-01488-7
更新日期:2020-11-01 00:00:00
abstract::This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite 0.15% (Alphagan P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan; Pfizer Inc., New York, NY( to patients with open-angle glaucoma or ocular hypertension. In this multicenter, ...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1007/BF02849898
更新日期:2007-03-01 00:00:00
abstract::The tolerability of brimonidine tartrate 0.15%--referred to as bromonidine-Purite 0.15% in this study--was compared with brimonidine tartrate 0.2% in irritated eyes of healthy volunteers as well as patients with glaucoma or ocular hypertension (N=20) in a 2-week, single-center, randomized, double-masked, crossover stu...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1007/BF02849799
更新日期:2003-11-01 00:00:00
abstract::Nateglinide is an oral antidiabetic medication that acts through rapid, short-term stimulation of insulin production. This study was undertaken to identify the incidence and nature of adverse effects of nateglinide and to assess its efficacy in clinical practice. Patients (n = 3254) were recruited from 606 centers in ...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/BF02849871
更新日期:2005-09-01 00:00:00
abstract:INTRODUCTION:This study aimed to demonstrate the clinical utility of non-invasive multigene Cxbladder urine tests in reducing the overall number of diagnostic tests and invasive procedures used in the clinical evaluation of patients presenting with microhematuria, a key symptom of urothelial carcinoma (UC). There is a ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-017-0518-7
更新日期:2017-05-01 00:00:00
abstract:INTRODUCTION:Oral supplementation of chondroitin sulfate (CS) and glucosamine (GlcN), symptomatic slow-acting molecules, is recommended by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and Musculoskeletal Diseases (ESCEO) and other European Union (EU) guidelines for the restorati...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01064-8
更新日期:2019-11-01 00:00:00
abstract:INTRODUCTION:To evaluate, from the patient's perspective, the burden of pain associated with hip/knee osteoarthritis (OA) in the USA and selected European Union (EU) countries. METHODS:Data were drawn from the 2017 global Adelphi OA Disease Specific Programme™ (DSP). Patients with hip/knee OA were stratified based on ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01445-4
更新日期:2020-09-01 00:00:00
abstract::The original article can be found online. ...
journal_title:Advances in therapy
pub_type: 杂志文章,已发布勘误
doi:10.1007/s12325-018-0767-0
更新日期:2018-09-01 00:00:00